Researches show that gypensapogenin A-liposomes activate FXR to inhibit CYP7A1/CYP8B1 yet induce CYP27A1, reducing total bile acid pool while increasing chenodeoxycholic acid content, ultimately lowering serum total cholesterol (TC) / triglycerides (TG) levels in NAFLD [117]. The gene discussed is CYP8B1; the disease is metabolic dysfunction-associated steatotic liver disease.